Summary
48.06 0.89(1.89%)07/17/2025
Bristol-Myers Squibb Company (BMY)
BMY reported last earnings on 2025-04-24 after the market. An EPS of $1.8 was observed compared to an estimated EPS of $1.49, resulting in a surprise value of $0.31. A revenue of $11,201 million was observed compared to an estimated revenue of $10,695 million, resulting in a surprise value of $506 Million.
Bristol-Myers Squibb Company (BMY)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years |
| -1.29 | 2.56 | 3.09 | -1.09 | -12.55 | 16.62 | -2.42 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan!
Fundamental Ratings
| Category | Rating |
| Main Rating | B+ |
| Recommended Rating | Neutral |
| DCF | Strong Buy |
| ROE | Strong Buy |
| ROA | Buy |
| Debt/Equity | Strong Sell |
| P/E | Sell |
| P/B | Strong Sell |
Earnings
| Trading Data | ||
| Close | 47.44 | |
| Open | 48.14 | |
| High | 48.23 | |
| Low | 47.26 | |
| Volume | 7,166,704 | |
| Change | -0.62 | |
| Change % | -1.29 | |
| Avg Volume (20 Days) | 14,986,327 | |
| Volume/Avg Volume (20 Days) Ratio | 0.48 | |
| 52 Week Range | 39.35 - 61.84 | |
| Price vs 52 Week High | -23.28% | |
| Price vs 52 Week Low | 20.57% | |
| Range | 0.00 | |
| Gap Up/Down | -0.61 | |
Profitibility | ||
| Market Capitalization (Mln) | 95,252 | |
| Revenue per share | 23.4545 | |
| Net Income per share | 2.6681 | |
| Dividend Yield | 0.0637 | |
| Dividend Share | 306.00% | |
Valuations | ||
| Enterprise Value | 0.00% | |
| PE Ratio | 18.0125 | |
| PB Ratio | 0.0000 | |
| PTB Ratio | 0.0000 | |
Liquidity | ||
| Debt/Equity Ratio | 0.0000 | |
| Net Debt/EBIDTA Ratio | 0.0000 | |
| Current Ratio | 0.0000 | |
Enterprise Value and Cash Flow | ||
| EV/Sales Ratio | 0.0000 | |
| EV/EBIDTA Ratio | 0.0000 | |
| EV/Free Cash Flow Ratio | 0.0000 | |
07/18 14:46 EST - seekingalpha.com
July's 5 Dividend Growth Stocks With Yields Up To 7.96%
Dividend growth stocks can offer a stable way to passively grow one's income, creating long-term compounding wealth over the long run. Today, we are looking at a screening process that focuses on higher yields but ranks higher on dividend safety and consistency for growth. From the hundreds that...
July's 5 Dividend Growth Stocks With Yields Up To 7.96%
Dividend growth stocks can offer a stable way to passively grow one's income, creating long-term compounding wealth over the long run. Today, we are looking at a screening process that focuses on higher yields but ranks higher on dividend safety and consistency for growth. From the hundreds that...
07/18 10:01 EST - zacks.com
Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It
Recently, Zacks.com users have been paying close attention to Bristol Myers (BMY). This makes it worthwhile to examine what the stock has in store.
Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It
Recently, Zacks.com users have been paying close attention to Bristol Myers (BMY). This makes it worthwhile to examine what the stock has in store.
07/18 06:59 EST - businesswire.com
Bristol Myers Squibb Announces Topline Results from Phase 3 INDEPENDENCE Trial for Reblozyl® (luspatercept-aamt) in Adult Patients with Myelofibrosis-Associated Anemia
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #Anemia--BMS Announces Topline Results from Phase 3 INDEPENDENCE Trial for Reblozyl in Adult Patients with Myelofibrosis-Associated Anemia.
Bristol Myers Squibb Announces Topline Results from Phase 3 INDEPENDENCE Trial for Reblozyl® (luspatercept-aamt) in Adult Patients with Myelofibrosis-Associated Anemia
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #Anemia--BMS Announces Topline Results from Phase 3 INDEPENDENCE Trial for Reblozyl in Adult Patients with Myelofibrosis-Associated Anemia.
07/18 06:43 EST - 247wallst.com
Boomers Get a Big Beautiful Tax Break: 4 Safe Stocks Yielding 5% to Buy Now
President Trump recently signed the “Big, Beautiful” bill, which introduces a temporary “senior bonus” deduction of up to $6,000 for individuals aged 65 and older ($12,000 for married couples filing jointly) for tax years 2025 through 2028.
Boomers Get a Big Beautiful Tax Break: 4 Safe Stocks Yielding 5% to Buy Now
President Trump recently signed the “Big, Beautiful” bill, which introduces a temporary “senior bonus” deduction of up to $6,000 for individuals aged 65 and older ($12,000 for married couples filing jointly) for tax years 2025 through 2028.
07/17 11:47 EST - cnbc.com
Bristol Myers Squibb, Pfizer to sell blockbuster blood thinner Eliquis at 40% discount
Bristol Myers Squibb and Pfizer said they will start selling their blockbuster blood thinner, Eliquis, directly to some patients at a more than 40% discount. The companies' new effort would bypass traditional middlemen, including pharmacy benefit managers and insurers, to cut the drug's monthly...
Bristol Myers Squibb, Pfizer to sell blockbuster blood thinner Eliquis at 40% discount
Bristol Myers Squibb and Pfizer said they will start selling their blockbuster blood thinner, Eliquis, directly to some patients at a more than 40% discount. The companies' new effort would bypass traditional middlemen, including pharmacy benefit managers and insurers, to cut the drug's monthly...
07/17 06:59 EST - businesswire.com
Bristol Myers Squibb and Pfizer Announce Direct-to-Patient Eliquis® (apixaban) Option
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb and Pfizer Announce Direct-to-Patient Eliquis® (apixaban) Option.
Bristol Myers Squibb and Pfizer Announce Direct-to-Patient Eliquis® (apixaban) Option
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb and Pfizer Announce Direct-to-Patient Eliquis® (apixaban) Option.
07/17 06:30 EST - wsj.com
Bristol-Myers Squibb and Pfizer plan to sell the widely used blood thinner Eliquis directly to patients at a discounted cash price
The joint venture is launching a direct-to-consumer service of Eliquis after discussions with the Trump administration.
Bristol-Myers Squibb and Pfizer plan to sell the widely used blood thinner Eliquis directly to patients at a discounted cash price
The joint venture is launching a direct-to-consumer service of Eliquis after discussions with the Trump administration.
07/16 09:46 EST - zacks.com
Will Increased Expenses Affect Bristol Myers' Performance?
BMY inks $3.5B bispecific antibody deal with BioNTech as top-line pressures and bottom-line risks mount.
Will Increased Expenses Affect Bristol Myers' Performance?
BMY inks $3.5B bispecific antibody deal with BioNTech as top-line pressures and bottom-line risks mount.
07/14 13:52 EST - benzinga.com
Is Bristol-Myers Squibb Still An Undervalued Biopharma Play?
Bristol-Myers Squibb & Co. BMY is gearing up to announce its second-quarter 2025 earnings on July 31, with expectations for adjusted earnings of $1.585 per share on sales of $11.31 billion, according to data from Benzinga Pro.
Is Bristol-Myers Squibb Still An Undervalued Biopharma Play?
Bristol-Myers Squibb & Co. BMY is gearing up to announce its second-quarter 2025 earnings on July 31, with expectations for adjusted earnings of $1.585 per share on sales of $11.31 billion, according to data from Benzinga Pro.
07/14 09:13 EST - 247wallst.com
$7.4 Trillion Is in Money Markets Now: When Rates Fall, These High-Yield Blue Chips Will Run
According to Yahoo Finance, the average annual percentage yield for high-yield money market accounts is currently around 4.30%, with some banks offering rates exceeding 5.00%.
$7.4 Trillion Is in Money Markets Now: When Rates Fall, These High-Yield Blue Chips Will Run
According to Yahoo Finance, the average annual percentage yield for high-yield money market accounts is currently around 4.30%, with some banks offering rates exceeding 5.00%.
07/11 11:00 EST - zacks.com
ABBV or BMY: Which Biopharma Giant Has Better Prospects for Now?
AbbVie edges ahead of Bristol Myers with strong Skyrizi and Rinvoq growth, offsetting Humira declines and portfolio headwinds.
ABBV or BMY: Which Biopharma Giant Has Better Prospects for Now?
AbbVie edges ahead of Bristol Myers with strong Skyrizi and Rinvoq growth, offsetting Humira declines and portfolio headwinds.
07/11 05:36 EST - fool.com
2 Top Stocks Down 16% and 17% This Year to Buy and Hold
Most people love a bargain; investors do too. Purchasing shares of companies that can perform well over long periods is already pretty exciting, but it's even more so when they can be scooped up from the discount bin.
2 Top Stocks Down 16% and 17% This Year to Buy and Hold
Most people love a bargain; investors do too. Purchasing shares of companies that can perform well over long periods is already pretty exciting, but it's even more so when they can be scooped up from the discount bin.
07/10 08:45 EST - seekingalpha.com
Dividend Harvesting Portfolio Week 227: $22,700 Allocated, $2,385.24 In Projected Dividends
The Dividend Harvesting Portfolio hit new all-time highs in value, profitability, and forward income, with a 29.58% return on invested capital. Consistent weekly investing, diversification, and a focus on income-producing assets have driven strong performance, even through volatile markets and...
Dividend Harvesting Portfolio Week 227: $22,700 Allocated, $2,385.24 In Projected Dividends
The Dividend Harvesting Portfolio hit new all-time highs in value, profitability, and forward income, with a 29.58% return on invested capital. Consistent weekly investing, diversification, and a focus on income-producing assets have driven strong performance, even through volatile markets and...
07/10 03:01 EST - seekingalpha.com
Bristol Myers Squibb: Hidden Facts Blur The Strength Of The Company
Bristol Myers Squibb is undervalued despite the looming patent cliff, as its robust pipeline and strong cash flow position it for future growth. The impact of Eliquis' patent expiry is overstated, since only half its revenue affects BMY's bottom line due to the Pfizer partnership. Earnings have...
Bristol Myers Squibb: Hidden Facts Blur The Strength Of The Company
Bristol Myers Squibb is undervalued despite the looming patent cliff, as its robust pipeline and strong cash flow position it for future growth. The impact of Eliquis' patent expiry is overstated, since only half its revenue affects BMY's bottom line due to the Pfizer partnership. Earnings have...
07/09 18:46 EST - zacks.com
Bristol Myers Squibb (BMY) Surpasses Market Returns: Some Facts Worth Knowing
In the closing of the recent trading day, Bristol Myers Squibb (BMY) stood at $47.66, denoting a +1.32% move from the preceding trading day.
Bristol Myers Squibb (BMY) Surpasses Market Returns: Some Facts Worth Knowing
In the closing of the recent trading day, Bristol Myers Squibb (BMY) stood at $47.66, denoting a +1.32% move from the preceding trading day.
07/09 10:20 EST - zacks.com
Will Recent Label Expansions of Opdivo Help BMY Gain Momentum?
BMY leans on Opdivo's solid growth and new approvals as generics pressure its other top drugs and shares remain under pressure.
Will Recent Label Expansions of Opdivo Help BMY Gain Momentum?
BMY leans on Opdivo's solid growth and new approvals as generics pressure its other top drugs and shares remain under pressure.
07/08 12:36 EST - seekingalpha.com
June Readers Tagged 13 Ideal Dividend Dogs From 16 "Safer" Out Of 38 ReFa/Ro
My contrarian yield-based strategy spotlights high-yield 'ReFa/Ro Dogs' with analyst forecasts suggesting 19-33% net gains by June 2026. All top ten ReFa/Ro Dogs offer annual dividends from $1,000 invested that exceed their share prices, meeting my 'ideal' stock criteria. Caution: Fourteen of...
June Readers Tagged 13 Ideal Dividend Dogs From 16 "Safer" Out Of 38 ReFa/Ro
My contrarian yield-based strategy spotlights high-yield 'ReFa/Ro Dogs' with analyst forecasts suggesting 19-33% net gains by June 2026. All top ten ReFa/Ro Dogs offer annual dividends from $1,000 invested that exceed their share prices, meeting my 'ideal' stock criteria. Caution: Fourteen of...
07/08 10:41 EST - cnbc.com
Healthy Returns: Medicaid cuts in Trump's megabill may affect some drugmakers more than others
Trump's "big beautiful" bill will also affect the pharmaceutical industry, while AI startups have pulled in the majority of digital health funding this year.
Healthy Returns: Medicaid cuts in Trump's megabill may affect some drugmakers more than others
Trump's "big beautiful" bill will also affect the pharmaceutical industry, while AI startups have pulled in the majority of digital health funding this year.